SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Reconciliation of Net Loss per Common Share (Details) - USD ($)		3 Months Ended				6 Months Ended
	Mar. 02, 2021	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2022	Jun. 30, 2021
Net income (loss)		$ 1,473,403	$ 3,573,339	$ (112,267)	$ (405,698)	$ 5,046,742	$ (517,965)
Accretion of temporary equity to redemption value		88,380		4,120		(91,783)	(13,385,719)
Net income (loss) including accretion of temporary equity to redemption value		1,385,023		(116,407)		4,954,959	(13,903,684)
Numerator:
Accretion of temporary equity to redemption value		(88,380)		(4,120)		91,783	13,385,719
Net income (loss)		1,473,403	$ 3,573,339	(112,267)	$ (405,698)	5,046,742	(517,965)
Class A ordinary shares
Net income (loss)		1,196,398		(88,986)		4,055,750	2,262,772
Accretion of temporary equity to redemption value		(88,380)		(4,140)		(91,783)	(13,385,719)
Numerator:
Allocation of net income (loss) including accretion of temporary equity		1,108,018		(93,126)		3,963,967	(11,122,947)
Accretion of temporary equity to redemption value		88,380		4,140		91,783	13,385,719
Net income (loss)		$ 1,196,398		$ (88,986)		$ 4,055,750	$ 2,262,772
Denominator:
Weighted average shares outstanding - basic		13,800,000		13,800,000		13,800,000	9,149,171
Weighted average shares outstanding - diluted		13,800,000		13,800,000		13,800,000	9,149,171
Basic and diluted net income (loss) per share - basic		$ 0.09		$ (0.01)		$ 0.29	$ 0.25
Basic and diluted net income (loss) per share - diluted		$ 0.09		$ (0.01)		$ 0.29	$ 0.25
Class B ordinary shares
Net income (loss)		$ 277,005		$ (23,281)		$ 990,992	$ (2,780,737)
Numerator:
Allocation of net income (loss) including accretion of temporary equity		277,005		(23,281)		990,992	(2,780,737)
Net income (loss)		$ 277,005		$ (23,281)		$ 990,992	$ (2,780,737)
Denominator:
Weighted average shares outstanding - basic		3,450,000		3,450,000		3,450,000	3,298,343
Weighted average shares outstanding - diluted		3,450,000		3,450,000		3,450,000	3,298,343
Basic and diluted net income (loss) per share - basic		$ 0.08		$ (0.01)		$ 0.29	$ (0.84)
Basic and diluted net income (loss) per share - diluted		$ 0.08		$ (0.01)		$ 0.29	$ (0.84)
Founder shares \| Over-allotment option
Denominator:
Shares no longer subject to forfeiture	450,000

IBERE PHARMACEUTICALS 10-Q